Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02724631
Other study ID # 14-011488
Secondary ID 5R44HD065365-04
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 2016
Est. completion date May 2024

Study information

Verified date June 2023
Source Children's Hospital of Philadelphia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is the first of three planned phases designed to evaluate the feasibility and tolerability of TubeClear® to restore patency in occluded Pediatric Enteral Access Devices. Based on preliminary data obtained from this phase of the study, subsequent phases will continue to evaluate feasibility and tolerability (Phase IIA) and ultimately compare efficacy of TubeClear® to the Children's Hospital of Philadelphia (CHOP) Standard Treatment to restore patency in occluded Pediatric Enteral Access Devices (EAD) (Phase IIB).


Description:

Occluded enteral access devices (EADs) are a significant problem for pediatric patients, with occlusion rates ranging from 12.5% to 35%. Occluded EADs can lead to extended times of decreased energy intake, resulting in patients quickly exhausting their energy reserves and developing dehydration with electrolyte abnormalities. Current methods used to restore patency to an occluded EAD at The Children's Hospital of Philadelphia (CHOP) involve application of enzymes and chemicals (e.g., Clog Zapper), which have variable rates of timely success. If these methods are unsuccessful and patency cannot be restored, the EAD must be replaced and may require radiological intervention with exposure to radiation and contrast material. TubeClear® addresses this clinical need to safely and efficaciously restore patency to occluded EADs at the patients' bedside while the EAD remains in the patient. Additionally, this reduces the need to transport the patient to the radiology suite with subsequent exposure to radiation and contrast material for EAD location conformation after replacement. Current Study (Phase I): Feasibility and tolerability of TubeClear® intervention in 15 consecutive eligible Subjects with occluded Enteral Access Devices who have not attained their 18th birthday. Following successful completion of Phase I as deemed by the Institutional Review Board (IRB), the Study will proceed to Phase IIA and IIB to run concurrently. Future Studies: Phase IIA: Ability of TubeClear® intervention to restore patency in 15 consecutive eligible Subjects with occluded Enteral Access Devices who have not attained their 11th birthday. Phase IIB: Randomized efficacy comparison between 17 subjects using the TubeClear® intervention and 17 subjects using CHOP Standard Treatment in eligible Subjects with occluded Enteral Access Devices who are between 11 years of age and have not attained their 18th birthday.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 15
Est. completion date May 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 0 Years to 17 Years
Eligibility Inclusion Criteria: 1. Males or females between who have not attained their 18th birthday 2. Indwelling occluded EAD(P) that is either: - Nasoduodenal Tube (ND), Nasogastric Tube (NG), Nasojejunal Tube (NJ) composed of Polyvinyl Chloride (PVC) and Polyurethane 6 - 8 Fr, 38 - 140 cm cm; or - Nasogastric Tube (NG) (Corflo, Corpak MedSystems) used as a jejunal tube inserted through a gastrostomy tube, 6 - 8 Fr, 38 - 140 cm - GJ (AMT) 14 Fr, 38 - 140 cm (15 - 55 in) Exclusion Criteria: 1. Ward of the state 2. Positive pregnancy test/ Pregnant females 3. Any active gastrointestinal abnormalities or malformations, including but not limited to infections, inflammation, obstruction and/or recent abdominal surgery or trauma 4. Constant dependency on the EAD(P) for a glucose source (e.g. hyperinsulinism states) 5. Unable to tolerate water volume needed for the EAD(P) flush 6. Allergies to the contrast agent(s) used in post-Intervention radiological imaging 7. Measured total length of EAD(P) less than 38 cm (15 inches) - from external port to EAD(P) distal end 8. Unknown length of EAD(P) 9. Attending physician declines enrollment based on clinical judgement 10. Subject attains 18 years of age during study duration

Study Design


Related Conditions & MeSH terms


Intervention

Device:
TubeClear® intervention
The TubeClear® device is deemed by the Food and Drug Administration (FDA) to be non-significant risk (NSR) for use in this study. It is a control box and a single use clearing stem used to resolve the clog in an enteral access device within five minutes following the intervention.

Locations

Country Name City State
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania

Sponsors (3)

Lead Sponsor Collaborator
Children's Hospital of Philadelphia Actuated Medical, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Successful Attempts to Restore EAD(P) Patency Feasibility will be defined as ability of the user to operate TubeClear® from clearing stem insertion into the occluded Enteral Access Device through activation to patency restoration. Successful restoration of patency will be defined as the ability to flush the EAD(P) with 10ml of air within five minutes following the intervention by the investigator. Baseline to 5 minutes post-intervention
Secondary Change in Age-Appropriate Pain Score Tolerability will be defined as ability of the subject to undergo TubeClear® intervention. To assess this, subject pain will be assessed before and after use of TubeClear® intervention and then daily for up to 3 days post-intervention using one of the well-established age-appropriate pain scales. Based on subject age, one of the following pain scale assessments will be used: Face, Legs, Activity, Cry, Consolability (FLACC) Scale; Revised Face, Legs, Activity, Cry, Consolability (rFLACC) scale; FACES pain scale revised (FPS-R); Numeric Pain Scale; or Nursing Judgement Baseline to 3 days post-intervention
See also
  Status Clinical Trial Phase
Completed NCT02913677 - Prolonged Minimal Enteral Nutrition Versus Slowly Advancing Enteral Nutrition in Very Low Birth Weight Infants: N/A
Not yet recruiting NCT00916591 - Prokinetic Drugs and Enteral Nutrition N/A
Completed NCT01025167 - The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and Chemotherapy in Cancer Patients N/A
Not yet recruiting NCT05900323 - Enteral Nutrition Guidelines and Patients' Outcomes N/A
Completed NCT03153397 - Effect of Prebiotic Fiber- Enriched (scFOS) Enteral Feeding on the Microbiome in Neurological Injury Trauma Patients (PreFEED Microbiome Trial) N/A
Completed NCT02353689 - The Effect of FODMAP Content in Tube Feeding Formula on Feeding Intolerance and Nutritional Status Improvement Phase 2/Phase 3
Terminated NCT00564655 - Regional Anesthesia Block of the Transversus Abdominis Plane in Children Undergoing Gastric Tube Insertion Phase 3
Completed NCT06134674 - Early Versus Delayed Enteral Nutrition in Critically Ill Adults With COVID-19
Recruiting NCT03791866 - The Th9/IL-9 and Early Enteral Nutrition in Sepsis N/A
Enrolling by invitation NCT06161350 - The Multi-disciplinary Approach of Children With Feeding Difficulties and Tube Feeding in UZB Between 2000 and 2021
Completed NCT01988792 - Human Milk Fortification in Very Low Birth Neonates N/A
Completed NCT00600678 - Gastric Emptying Study After Administration of a High Caloric Sip Feed N/A
Completed NCT02998931 - Trial of Enteral Glutamine on Clinical Outcomes in Critically Ill Patients Phase 3
Not yet recruiting NCT06411873 - The Effect of High Protein Enteral Nutrition on Critically Ill Postoperative Children N/A
Recruiting NCT03176875 - Comparison of Partial and Exclusive Enteral Nutrition in the Treatment of Active Childhood-onset Crohn's Disease N/A
Completed NCT02779335 - Enteral Formula Tolerance in Pediatric Patients N/A
Completed NCT05411848 - 2kcal Tube Feed Study N/A
Completed NCT04868318 - The Impact of Intervention With High-protein Enteral Formula in SICU. N/A
Withdrawn NCT04601571 - Confirming Feeding Tube Position Using CORTRAK N/A
Not yet recruiting NCT06239610 - DrIFT 2 Study: Displacement in Feeding Tubes N/A